BOULDER, Colo., May 24, 2021 /PRNewswire/ — Arthritis is one of the most widespread health conditions in the United States and affects one in four adults, according to the CDC. That’s over 54 million men and women. There are common misconceptions around Arthritis, including what it’s like to live with it. ArthroCBD recently performed quantitative and qualitative studies to “debunk” these myths.  Throughout the month, ArthroCBD will share details of the findings as part of the “Celebrate Life Without Compromises” campaign.

A common myth is that arthritis only impacts the hands and knees. While the majority of people experience this, symptoms can be felt anywhere on the body and weight-bearing joints are the most common. Research shows that symptoms are most present in the form of joint pain and inflammation, which commonly occur in the knees, hands, hips and along the spine.

Another misconception about living with arthritis is that it’s just pain, and you should be able to work through it. One patient surveyed by Opticann says, “it can feel like a constant aching pain and stiffness… it hurts every day.”

15% of those surveyed experience pain in their feet and almost all of them (94%) report that they are frequently in pain. 26% of those surveyed report pain in their torso, head or shoulders. Those who experience pain in these areas experience it more frequently, with half managing their pain on a daily basis.

While there are stigmas to challenge, arthritis and pain sufferers are empowered to find their best treatment option. Research shows that ‘long-term relief’ and ‘limited side effects’ are rated as the most important treatment characteristics. Most arthritis and pain patients have tried between 2-4 different types of treatment for their condition. 32% of people stop after they have tried one treatment, and only 11% of pain and arthritis sufferers surveyed are happy with their current pain treatment.

When it comes to CBD based healthcare products, 97% of consumers with Arthritis are interested in learning more. Only 15% have tried CBD. Four in every five respondents feel confident making their treatment decisions on their own.

The compelling data showed that patients are interested in finding solutions that are well tested and safe without harsh impact to their bodies. ArthroCBD hopes to be a solution for those seeking symptomatic relief and will continue to prioritize research and clinical studies to do so.

About ArthroCBD

ArthroCBD is a subsidiary of Opticann Inc., a Colorado-based oral and topical cannabinoid company. Opticann sells science-backed products made with the patented VESIsorb® drug delivery system for optimized absorption and stability (bioavailability). Opticann is owned by Heritage Cannabis Holdings Corp., a Toronto-based publicly traded corporation (CSE: CANN) (OTCQX: HERTF). Opticann represents the firm’s US medicinal approach to meet consumer needs.

For more information, please visit arthrocbd.com

CONTACT: Alexis Woody
[email protected]
201-241-2668

SOURCE OptiCann

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis has been used for thousands of years. From native Indians to various subcultures, people have used cannabis for several reasons. However, there has always been a stigma surrounding cannabis use. Although a lot of people used the plant, it was never widely accepted by the general public.

However, things started changing in the last 40 years. Today there are many countries in which medical cannabis is legal, and there’s tons of research about this plant and its benefits. This change is obvious for another reason as well, currently there are thousands of medical dispensaries where people can legally buy cannabis.

For example, residents of California can drop by Venice Beach cannabis dispensary and instantly get cannabis for their needs. One of the reasons these medical dispensaries are so popular is because they promote responsible cannabis use. Here’s how they work.

They Offer Better Product Quality

In the past, people had to get cannabis from unreliable sources and shady channels. Simply put, there wasn’t a legal way to get marijuana, which made it difficult to find quality products along with a reliable source they could always count on.

It was also very unsafe. People had issues because they often bought low-quality products with no guarantee of what they were getting. People had to trust that the seller would deliver good quality. Today, products at medical dispensaries come from professional breeders and cultivators.

Customers know the exact strain they are getting and these producers are held to a higher standard. Simply put, they need to pass various quality checks to be able to sell their products.

They are Safer

Using cannabis responsibly is not just about having a reliable supplier – the way you get your products matters as well. Whenever illegal production and supply are involved, there are certain risks for everyone, including consumers.

As a buyer you don’t want to meet someone in the back alley, not knowing what to expect. You can potentially get robbed, scammed or even arrested if cannabis is illegal. Medical dispensaries are far safer. First of all, the cannabis they sell is completely legal and legit.

You don’t have to worry about being scammed. You can just drop by and purchase the product you need. At the same time, dispensaries often have security personnel and cameras that protect you from potential criminals.

You Know What You are Getting

Dispensaries must be transparent. What does this mean? A couple of things:

• Every medicine and product that’s being sold goes through rigorous checks.
• The origin of each product can be traced back to the producer.
• Product packaging clearly states the content of the product and all its ingredients.
• If you have additional questions, you can talk to the pharmacist working at the dispensary

When buying medical products you need to know what they contain, since people use cannabis for treating different conditions. Professional producers breed different strains that are better at alleviating various symptoms.

For example, some marijuana strains are better for treating depression and anxiety while others might be better for arthritis. You can always find a product that’s best for your needs.

Dispensaries Can Educate Users on Proper Cannabis Use

Dispensaries often have medical professionals working at them. These pharmacists are there to accept various medical forms and prescriptions that people use to get their medical products. However, there is another advantage of having medical professionals at the dispensary.

They have a lot of knowledge about different medications, how they work, and how they should be used. So, you’re not buying cannabis products from a random person – you’re getting it from people who have a medical background.

They can give you valuable advice on how to use your medicine properly, which is especially important when you’re taking cannabis for the first time and don’t know what to expect. A pharmacist can help you understand how you should use your medicine, when, and in what dosage.

Chances are you’ve heard about various cannabis side-effects, but in reality most of them are caused by improper use. People take high doses in uncontrolled environments and they suffer the consequences. A medical professional can guide you to avoid this from happening.

Bottom Line

The use of cannabis for medical purposes has gone a long way. All over the world, we are seeing more and more countries letting people treat several conditions with this medication. At the same time, we are also seeing an increase in cannabis-based drugs.

Dispensaries have made supply a lot easier to obtain. They make these products available to everyone who has an appropriate medical prescription. At the same time, people can use cannabis responsibly to get the desired effects.

Cannabidiol, better known as CBD, has become one of the most popular wellness products in the United States over the past couple of years. BDS Analytics and Arcview Market Research expect CBD sales to grow at a 49% compound annual growth rate to surpass $20 billion by 2024—making up about half of the total cannabinoid industry—as sales shift from cannabis dispensaries to pharmacy and grocery stores.

CaniBrands brings extensive consumer packaged goods and branding experience to the CBD space, where it has developed a science-based product line encompassing numerous form factors and proprietary formulations. The company’s Can-i products are supported by 12-time Olympic medalist Dara Torres—its Global Spokesperson—and acclaimed high-performance trainer, Andy O’Brien—its Sports Science Advisor.

In a recent interview with CFN Media, Co-Founder and CEO Chris Lords discusses the company’s unique approach to the market and growing product line:

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public

Holistic Approach with Many Choices

CaniBrands offers a premium product line that includes Can-i Boost, Can-i Sleep, Can-i Mend and Can-i Fresh, which are scientifically-formulated to deliver specific wellness benefits.

The company’s best-seller by revenue, Can-i Boost, combines hemp-derived CBD with a powerful blend of vitamins and herbal extracts designed to keep you alert, energized and clear-headed without any crashes or jitters. Meanwhile, the company’s best-seller by volume, Can-i Sleep, combines the same hemp-derived CBD with melatonin and other supplements designed to promote a healthy sleep cycle.

In addition to these best-selling products, the company’s Can-i Mend addresses pain, inflammation and soreness by accelerating the body’s healing process. The product is popular among athletes looking to cut recovery time and reduce post-workout soreness. And finally, the company’s Can-i Fresh is designed to deliver antioxidants, support the immune system and promote mental clarity on a day-to-day basis.

These products are available in multiple form factors, including a sublingual tincture, oral spray and cream, providing customers with many different choices. For example, many athletes appreciate creams to provide localized pain relief, whereas oral sprays provide a convenient on-the-go form factor for busy people. All of these products can be helpful at different times of the day from Can-i Boost in the morning to Can-i Sleep at night.

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public 

Active Expansion into New Markets

CaniBrands has been actively focused on establishing new distribution channels, expanding into new markets and launch new product lines.

The company began by building their own direct-to-consumer platform before moving onto Amazon Prime to access more households. Pilot programs are exploring the possibility of home delivery reselling in local markets, as well as online affiliate marketing, which could significantly expand its distribution and reach new customers throughout the United States that may not otherwise find them online.

Early next year, the company plans to launch its products in Canada before expanding into other international markets. The company’s Brand Ambassador, former NHL player and media personality Paul Bissonnette, will be integral in supporting the Canadian launch. Since becoming the first country to legalize recreational cannabis, Canada has been widely considered a leading market for cannabinoid-based products.

The company also aims to launch a variety of new product lines over time. For example, the company is exploring softgels, beverage, and other product formats (e.g. topicals, bars, and powders), as well as products containing other cannabinoids (e.g. CBN or CBG). The company’s CaniBuy ecommerce management platform also aims to integrate websites, ecommerce, payments and fulfillment into a single client-facing portal.

Gearing Up to Go Public in the Near-term

CaniBrands recently began a $5 million capital raise targeting accredited investors, and the founders and two strategic investors have already committed more than $1 million of the funding round. Management says that the proceeds will be put towards a variety of revenue-driving activities, as well as R&D and general operational expenses.

With no long-term debt, a seasoned management team, commercial products and a solid business model, the company is well-positioned to capitalize on the rapid growth of the CBD market over the coming years.

Accredited investors that are interested in participating in the funding round are encouraged to sign up to receive an investor presentation and corporate updates.

Are you an accredited investor? Learn how to invest in CaniBrands before it goes public

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Only days after announcing that its wholly owned subsidiary was awarded a German cannabis and cultivation and extraction licence, XPhyto Therapeutics is ready to enter the public domain. With a final prospectus filed with the British Columbia Securities Commission, XPhyto is ready to go public on the CSE under the ticker “XPHY”. The company will begin trading on the CSE on Tuesday, August 6, 2019.

Dual Market Focus: Germany

From its corporate headquarters in Vancouver, XPhyto is developing its business as a leader in formulation, processing, and clinical validation in two of the world’s most active markets, Canada and Germany. Germany, the largest economy in the European Union and second largest federally regulated medical cannabis market in the world (behind the U.S.), is seeing tremendous acceleration in cannabis demand, including importing nearly 2,500 kilograms for medical purposes in the first half of 2019. That’s almost as much as was imported in all of 2018 and more than twice as much as 2017.

Germany Flag on cannabis background. Drug policy. Legalization of marijuana

Click here to receive an investor deck and going public alert

Right now, Germany relies 100% on imports to supply is burgeoning medical cannabis market. Based upon some recently issued licenses, it will be until at least late in 2020 before any domestic cannabis will be available for medical purposes.

It is this growth that underscores Arcview Market Research forecasting Germany’s cannabis market to experience a whopping 76.8% compound annual growth rate to reach $1.6 billion by 2022.

Last Wednesday, the Company announced that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH, was awarded a cannabis cultivation and extraction licence for scientific purposes from the German Federal Institute for Drugs and Medical Devices, better known as BfArM. Bunker still has to pass BfArM’s security requirements, which isn’t expected to be an issue considering the company operates from a monitored high-security area in Bavaria that previously served as a German air force command center and nuclear bunker.

Bunker has a long-term lease for the entire facility with 10,741 square feet for the initial buildout and nearby space available for expansion.

The new licence authorizes Bunker to cultivate and extract up to 70 different strains of cannabis sativa and indica for scientific R&D.

With the new licence in tow, Bunker is next applying for licenses that will allow for cannabis import, storage, distribution and manufacturing. The license estate is at the heart of Bunker’s plans to serve as a one-stop shop providing a bevy of products and services spanning genetic research and storage, cultivation, extraction, storage, processing, packaging, distribution and more.

Click here to receive an investor deck and going public alert

Dual Market Focus: Canada

Canada made history last year when it became the first G7 country to legalize adult-use marijuana. Supply shortages and regulatory challenges kept the industry from getting off to the rip-roaring start analysts expected, but that hasn’t stopped Arcview Market Research and partner BDS Analytics from forecasting the Canadian cannabis market reaching $5.2 billion by 2024.

XPhyto’s operations in Canada are centered on in-house production of pharmaceutical-grade cannabis-derived compounds, developing proprietary formulas and conducting modern clinical research for diseases and conditions with unmet medical need where cannabis could be a viable option. They also offer third-party commercial analytical testing for licensed producers, wholesalers, distributors and law enforcement.

Management is advancing these operations through strategic collaborations that accelerate the process with other collateral benefits. For instance, XPhyto has two five-year agreements with the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences. This partnership provides XPhyto with certified analytical testing capability, as well as a certified extraction, isolation, and formulation facility.

Click here to receive an investor deck and going public alert

This is a tremendous capital saver for XPhyto as its cost to entry pales in comparison to the value of the world-class infrastructure, not to mention potential maintenance costs in the future. Furthermore, The University of Alberta is well known for its expertise in biopharmaceutics, drug delivery quality control and regulatory sciences.  An authority like that as a strategic partner gives XPhyto immediate brand recognition as a high quality service provider and access to talent that other companies simply do not easily come by.

Public Soon

XPhyto is hitting the ground running when it comes public as it looks to fill a void between cannabis and modern medical science. They have secured a collaborative partner in the esteemed experts at the University of Alberta to capitalize on the opportunity with minimal capex while the Bunker acquisition – along with its assets – give XPhyto a first mover advantage in the burgeoning German market.

XPhyto will commence trading on the CSE on Tuesday, August 6, 2019, which should have investors keen to participate in the next wave of cannabis opportunities – medical formulations and emerging European markets.

Click here to receive an investor deck and going public alert

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Believe it or not, the world’s first blockbuster drug is still one of the most commonly used today. Acetylsalicylic acid, better known as Aspirin®, is a synthetic derivative of the natural substance salicylic acid, an extract from the bark of the white willow tree. Any company would like to invent a drug that enjoys 100+ years of massive global usage and the possibility exists that cannabis could play a role in making that happen for someone.

Charting a Similar Path

People have been using salicylic acid to treat inflammation and fevers for over 2,400 years.  That’s right, when Greek engineers invented the catapult about 400 B.C., they may have used salicylic acid to treat their achy joints after moving some heavy rocks into position. Later, chemist Charles Frédéric Gerhardt made a breakthrough in 1853 by creating acetylsalicylic acid for the first time.  By 1899, Bayer dialed-in the chemical structure and was selling Aspirin® to the world.

Hemp, a cousin to cannabis that lacks tetrahydrocannabinol (THC), the cannabinoid responsible for the psychoactive high in marijuana, is regarded as one of the world’s oldest industrial crops.  It’s history dates back more than 10,000 years.

About 8,000 years ago, cannabis seeds and oil were used for food in China, with the first documented use of medical cannabis happening by Chinese Emperor Shen Neng roughly 4,750 years ago.  Interestingly, the Chinese world for “anesthesia” (mázui 麻) translates to “cannabis intoxication” because it was used to sedate people (along with wine) before surgery.

Now that the ending of cannabis prohibition is sweeping the globe, there has been a huge upswing in laboratory and clinical research as biotechs and pharmas seek to bring new cannabis-based products to market.  Will one of these drugs become the next aspirin?

Massive Potential

In an interview with Bloomberg, Marc Feldmann, an immunologist who helped discover a class of drugs that includes the blockbusters Humira and Remicade, commented that there is “massive potential” for the medical uses related to cannabis. Dr. Feldman now has dedicated himself to the market opportunity, teaming with cannabis researcher legend Dr. Raphael Mechoulam to start Toronto-based CannBioRex Pharmaceuticals.

While most companies are looking to the cannabis plant for active ingredients, Dr. Feldmann believes that the key to a new class of drugs resides in synthetic cannabis.

Dr. Joseph Tucker, an experienced executive and expert in synthetic active pharmaceutical ingredients (APIs) and drug development and commercialization, shares the view of Dr. Feldmann insomuch that synthetic cannabis represents the future for purity and repeatability in cannabis-based drug development.  Dr. Tucker is the Executive Chair and Co-Founder of Willow Biosciences (CSE: WLLW)(OTC: CANSF) with the purpose of becoming the largest manufacturer of biosynthetically produced cannabinoids.

Click here to receive an investor deck and corporate updates

The synthetic biology company was formed this year through the merger of BIOCAN Technologies: a team of experienced executives from Calgary and researchers from the University of British Columbia, and Epimeron: a team of researchers from the University of Calgary in Alberta, Canada.

“In addition to consistency and reproducibility, synthetic cannabis can be a much more cost-effective process than plant-based extraction or chemical synthesis, the only options that companies have today,” said Dr. Tucker in a phone interview with CFN Media. “Based on our estimates, biosynthetic production is about 90% faster and cheaper than plant-based extraction. We are of the opinion that synthetic processes will ultimately re-shape how cannabinoids are produced and open new gateways to advanced pharmaceutical opportunities to help people in medical need.”

Willow’s scientific progress is complemented by a team of experts in other areas of business, including CEO Trevor Peters. Peters has co-founded four startups in the last 15 years and been involved in corporate exits totaling more than $4 billion. He was most recently CFO at Caracal Energy, a London listed energy company which Glencore (OTCQX: GLNCY) bought in 2014 for $1.4 billion.

“We’ve got a great, well-rounded team at Willow Biosciences that can execute on our initiatives,” said Dr. Tucker. “There is a growing library of evidence to the effectiveness of cannabinoids.  This will provide tailwinds for drug companies to push hard to utilize cannabinoids in new therapeutics, which should have us well positioned to fill future demand.”

Click here to receive an investor deck and corporate updates

How Massive is Massive?

Clinically speaking, there are more than 300 cannabidiol (CBD) and other cannabinoid-based treatment options currently in human trials for indications such as PTSD, epilepsy, Parkinson’s disease, chronic pain, schizophrenia and others. The APIs are being sourced from traditional methods, which keeps research on promising rarer cannabinoids out of reach.  In order to tap into this market, an economically viable production method, like synthesis, is necessary.

Historic sales of cannabis-related drugs have been splotchy at best. The market for Marinol (dronabinol), a synthetic pill based on tetrahydrocannabinol (THC) and approved in 1998 for treating nausea and vomiting in cancer patients and anorexia in AIDS patients, was about $150 million in 2016.

On the other hand, analysts are higher on new drugs.  Evaluate Pharma forecasts that Epidiolex, the novel CBD drug of GW Pharma (NASDAQ: GWPH) approved last year by the FDA for treating two rare forms of childhood epilepsy, will reach blockbuster status with sales topping $1 billion in 2021.

More broadly, the U.S. cannabinoid-based pharmaceuticals market size is projected to grow to $50 billion annually by 2029, according to Ackrell Capital’s 2018 Cannabis Investment Report.  Analysts at Cowen predict that U.S. retail sales of CBD will reach $16 billion by 2025.

Willow Biosciences plan is to be a leading player catering to both markets.  In order to achieve this goal, Willow last month partnered with Noramco, the largest supplier of controlled substance APIs in the U.S. and biggest producer of pharmaceutical APIs in the world. Specifically, the two will work collaboratively to develop a yeast-based biosynthesis platform for the production and distribution of CBD.

Noramco is stepping up to tap into this burgeoning market. Per the accord, Willow will take care of expenses related to optimizing the yeast strains and Noramco will take it from there.  Noramco will cover the costs for scale-up, regulatory submission, marketing and distribution through its extensive global network.

The beauty of the deal for a small company like Willow Biosciences is that both partners will share equally in the profits.

Click here to receive an investor deck and corporate updates

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

 Jushi Holdings Inc. (NEO: JUSH) made its public debut on Monday, June 10^th.  The Boca Raton-based company has assembled a highly skilled and diversified team that is moving with a purpose, building a global footprint via organic and inorganic growth to capitalize on booming demand for cannabidiol, or CBD, in North America and abroad.

According to Cowen Equity Research and Marijuana Business Daily, global legal cannabis sales are forecasted to climb from about $9.6 billion in 2017 to $75 billion in 2030. In our opinion, there is no better time to be invested in this burgeoning industry.

Additionally, CBD is a non-psychotropic molecule found in cannabis and hemp.  The US Farm Bill, passed in December 2018, allowed, states to legalize industrial hemp and CBD products within their state paving the way for interstate commerce, while setting off a race to develop new products from hemp-derived CBD.

According to a report by market analysts at the Brightfield Group published in September 2018, hemp-based CBD is expected to blossom from around $600 million in 2018 to $22 billion by 2022.

Please click here to receive an investor deck and corporate updates

Operations Across the United States

Jushi and its portfolio companies have hemp operations in New York and are in the process of securing cannabis operations in California, New York, Virginia, Pennsylvania, Ohio, and Nevada as well as additional states.  The targets in California, the biggest cannabis market in North America, include several handpicked retail cannabis locations with delivery capabilities and licenses for distribution, cultivation and processing.

In the East, Jushi is emerging as a leading player through its acquisition of Mend Products, formation of its hemp-centric subsidiary, Sound Wellness Holdings, Inc. earlier this year, and its relationship with the DENT Neurologic Institute in Buffalo, NY.

Quality is a differentiator for Jushi. All Jushi products are tested by an independent third party to ensure consistency for its premium goods, which cover the full spectrum, including oils, soft gel caps, creams, tinctures and more.  Most products on the market today do not go through any independent testing to ensure consistency across batches, safety and quality, or even CBD levels.

Meanwhile, the company’s subsidiary Sound Wellness, LLC, which earned a hemp processing license through NY’s Industrial Hemp Agricultural Research program, is moving forward with its own hemp/CBD manufacturing facility in upstate New York.  When completed, Sound Wellness will have one of the largest industrial hemp processing, extraction and manufacturing operations in the Northeastern United States.

Please click here to receive an investor deck and corporate updates

Scientific Commitment to Health and Wellness

Coupled with savvy acquisitions, partnerships and key hires, Jushi has access to private research thanks in part to Jushi’s Medical Director, Dr. Laszlo Mechtler, and Jushi’s Medical President, Steven Przybyla.  Dr. Mechtler, a world-renowned expert in cannabis and cannabis research, was a founder of Mend and still serves as Medical Director at the DENT Neurologic Institute, operator of the largest medical cannabis program in New York.

With Dr. Mechtler’s oversight, the full-spectrum CBD-hemp derived products of Mend are formulated using patient data collected from thousands of patients and formulated by board-certified physicians with a dynamic process for revisions based upon new data.  Dent’s large pool of patient data indicates substantial benefits from cannabis-derived products.  Further, Dent and Mend are in the process of initiating groundbreaking research through two planned clinical studies into the impact of Mend products.

Prior to taking on the role of President of Jushi Medical, Steven Przybyla worked as EVP of Business Development, General Counsel and Director of Cannabis Programs at DENT, strengthening the ties between Jushi and the prestigious institution.

The Mend Store held its grand opening in Dent Tower in Buffalo on June 3, 2019. While open to public, the Mend Store also expects to serve patients of DENT’s medical cannabis program. Sales have started strong and are exceeding internal estimates.

Other initiatives of the company include international expansion by Jushi Europe, which will be focused on an early stage market through a separately financed entity.

Elsewhere, Jushi recently acquired the trademarks The Clinic^TM, The Clinic Consulting Services^TM, The Bank^TM and The Lab^TM as well as, subject to certain limited exceptions, intellectual property derived from the operations of The Clinic^TM Colorado. The Clinic Colorado, a Denver-based cannabis company, is known for its intellectual property concerning cannabis cultivation, processing, retail distribution, compliance, and safety in multiple states, and has received more industry awards than any other cannabis company in the US with 32 first place awards. The Clinic Colorado has had a track record of success with The Bank^TM owning intellectual property to cultivation and genetics of over 150 different strains and the Lab’s^TM intellectual property consisting of proprietary concentrates and extraction techniques. This sophisticated IP will complement Jushi’s expanding platform.

Please click here to receive an investor deck and corporate updates

The Upshot

Piloted by Deutsche Bank corporate finance veteran Erich Mauff (Founder, President, Board Member) and experienced hedge fund manager Jim Cacioppo (Founder, CEO, Chairman of the Board), Jushi combines public company and capital markets know-how with an excellent mix of cannabis and medical executives to create a multi-state operator with a commitment to shareholder value and highest quality products.

These fundamentals underpin management and advisors investing more than $20 million of the approximately $135 million that Jushi raised since February 2018 to support growth through its diverse capital allocation methodology. With Jushi recently going public on Monday, June 10th, keep an eye on further developments as the company executes its vision of becoming a bold, new, principled leader in the cannabis and hemp industry.

Please click here to receive an investor deck and corporate updates

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Nabis Holdings Inc. (CSE: NAB) was founded by two of the four founders of MPX Bioceutical Corp. (CSE: MPX), which was one of the first companies to successfully become a multi-state operator, or MSO, in the United States. In October 2018, MPX was acquired by iAnthus Capital Holdings Inc. (OTCQX: ITHUF) for C$835 million in equity, making it one of the largest acquisitions made in the United States cannabis industry.

CFN Media recently caught up with Nabis Holdings President Mark Krytiuk at this year’s Benzinga Cannabis Capital Conference to discuss Nabis Holdings and the founders’ goal to repeat and exceed their success with MPX.

Why Multi-State Operators?

The United States cannabis industry is projected to reach $25 billion by 2025, according to New Frontier Data, driven by the legalization of recreational and medical cannabis across a growing number of jurisdictions. While many cannabis operations began as local businesses in a single state, multi-state operators, or MSOs, have become increasingly commonplace, leveraging their capital and expertise across multiple states.

Last year, a record number of U.S. companies listed on the Canadian Securities Exchange (CSE) to raise capital to deploy into building a presence in the United States. MSOs accounted for the top five capital raises on the exchange, totaling $1.52 billion, according to MJBizDaily, and these trends are poised to continue into 2019. Many of these companies are focused on states such as California with expanding programs or newly legal states like Florida.

The problem for investors is that competition is fierce and many MSOs are led by inexperienced management teams. While these companies may be proficient at raising capital, many teams lack industry-specific experience that’s critical to create lasting brands. Many teams also lack the regulatory know-how to navigate complex interstate issues given the lack of a cohesive legalization framework on a national level.

Repeating the Success at MPX

Nabis Holdings’ founders aim to repeat & exceed the success of MPX by following a similar playbook — which shouldn’t be surprising given that ‘nabis’ means ‘repeat performance’. By acquiring high-quality cannabis assets across the United States, the company aims to become a leading multi-state operator with a focus on acquiring EBITDA-positive operations with proven operating experience and strong brand traction.

The company’s management team will assist portfolio companies in enhancing their operational pedigree. CEO Shay Shnet was VP of Operations at MPX and was instrumental in identifying unique opportunities, while President Mark Krytiuk was VP of Grow Operations and brings more direct experience in cultivation. The company will also leverage potential synergies between its portfolio companies to enhance overall value.

So far, the company has completed a number of acquisitions in Washington State and executed binding letters of intent to acquire vertically-integrated assets in Michigan and Arizona. In addition, the company is looking at several other ‘off market’ opportunities in states like California, Oregon, Oklahoma, Ohio, and Nevada. The goal is to reach C$14.8 million in 2019 revenue and C$167 million in 2020 revenue with 55% gross margins.

Looking Ahead

Nabis Holdings Inc. (CSE: NAB) has what many cannabis companies lack — an experienced management team that has done it before. By leveraging this experience, the company aims to repeat its success in building a leading U.S. presence in mission-critical states like Michigan, California, and Arizona. Investors may want to keep an eye on the stock given the company’s near-term catalysts as it moves from LOIs to tangible acquisitions.

For more information, visit the company’s website at www.nabisholdings.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.